Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05720325 · ClinicalTrials.gov registry record · Phase 2
Dupilumab Effects Against Aeroallergen Challenge
A Phase 2 study of Asthma, Allergic, sponsored by The University of Texas Health Science Center at San Antonio.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 88
- Enrollment target
- 2
- Study locations
NCT05720325 is a Phase 2 study of Asthma, Allergic that is actively recruiting participants, run by The University of Texas Health Science Center at San Antonio. The registered enrollment target is 88 participants. The trial reports 2 study locations across 1 state.
The verdict
NCT05720325, a Phase 2 study of Asthma, Allergic, is actively recruiting participants, sponsored by The University of Texas Health Science Center at San Antonio.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 88 participants
- Enrollment target
- 2
- Study locations
Study Summary
The trial involves two interventions: (i) exposure to HDM in the ACC and (ii) administration of dupilumab/placebo for dupilumab.
Conditions Studied
Interventions
- OTHER Placebo
- DRUG Dupilumab
- OTHER House Dust Mites (HDM)
Study Locations (2)
Texas
- Biogenics Research Chamber - San Antonio
- University of Texas Health Science Center at San Antonio - San Antonio
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 88 participants |
| Start Date | 2023-03-29 |
| Est. Completion | 2027-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05720325
The ClinicalTrials.gov registry entry for NCT05720325 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 88 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is The University of Texas Health Science Center at San Antonio, which has 378 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Asthma, Allergic appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT05720325 reports 2 study locations spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT05720325 about?
NCT05720325 is a clinical study titled "Dupilumab Effects Against Aeroallergen Challenge". The trial involves two interventions: (i) exposure to HDM in the ACC and (ii) administration of dupilumab/placebo for dupilumab.
What is the current status of trial NCT05720325?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 88 participants. The study started on 2023-03-29. Estimated completion is 2027-11.
What conditions does trial NCT05720325 study?
This clinical trial studies the following conditions: Asthma, Allergic.
What interventions are being tested in trial NCT05720325?
The interventions under investigation include: Placebo (OTHER), Dupilumab (DRUG), House Dust Mites (HDM) (OTHER).
Who is sponsoring clinical trial NCT05720325?
This trial is sponsored by The University of Texas Health Science Center at San Antonio, which has 378 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05720325 being conducted?
This trial has 2 study locations across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Asthma, Allergic
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.